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Background: Umbilical cord blood (UCB) is an important source of hematopoietic stem cells (HSCs). However, the
concentration of cells in cord blood units is limited and this may represent the main restriction to their therapeutic
clinical use. The percentage of metabolically active stem cells provides a measure of the viability of cells in an UCB
sample. It follows that an active cellular metabolism causes a proliferation in stem cells, offering an opportunity to
increase the cellular concentration. A high cell dose is essential when transplanting cord stem cells, guaranteeing,
in the receiving patient, a successful outcome.
This study is designed to evaluate the impact of docosahexaenoic acid (DHA) supplementation in pregnant
women, in order to increase the quantity and viability of the cells in UCB samples.
Methods/design: The metabolic demand of DHA increases in the course of pregnancy and reaches maximum
absorption during the third trimester of pregnancy. According to these observations, this trial will be divided into
two different experimental groups: in the first group, participants will be enrolled from the 20th week of estimated
stage of gestation, before the maximum absorption of DHA; while in the second group, enrolment will start from
the 28th week of estimated stage of gestation, when the DHA request is higher. Participants in the trial will be
divided and randomly assigned to the placebo group or to the experimental group. Each participant will receive a
complete set of capsules of either placebo (250 mg of olive oil) or DHA (250 mg), to take one a day from the 20th
or from the 28th week, up to the 40th week of estimated gestational age. Samples of venous blood will be taken
from all participants before taking placebo or DHA, at the 20th or at the 28th week, and at the 37th to 38th week
of pregnancy to monitor the level of DHA. Cell number and cellular viability will be evaluated by flow cytometry
within 48 hours of the UCB sample collection.
Trial registration: International Standard Randomised Controlled Trial Number Register: ISRCTN58396079.
Registration date: 8 October 2013.* Correspondence: martini@smartbank.it
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Figure 1 Chemical structure of docosahexaenoic acid (DHA).
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Umbilical cord blood (UCB) cells provide an alternative
source of hematopoietic stem cells (HSCs) for those pa-
tients with hematologic diseases unable to find a fully
compatible donor.
Over the last 25 years, the field of UCB banking and
transplantation has grown exponentially [1]. However,
despite the successes, one of the main problems with
using UCB for transplantation is related to the reduced
number of hematopoietic progenitor cells (HPCs) and
HSCs compared with bone marrow or mobilized periph-
eral blood grafts.
The risk of graft failure increases with the limited
number of available HPCs and HSCs, including delayed
hematopoietic engraftment [2-4] and delayed immune
reconstitution [5,6]. The studies show a cumulative inci-
dence of nonengraftment that ranges from 10 to 20%
after UCB transplantation, while the median time for
neutrophil recovery is between 22 and 27 days.
Protocols on intravenous CD34+ stem cell transplants
specify a minimum dose equivalent to 3 × 107 mono-
nuclear cells/kg of body weight and 1.5 × 105 CD34+/kg
of the patient’s weight at the time of the infusion. Umbil-
ical cord collections are 11 × 108 mononuclear total num-
ber of cells and 3 × 106 CD34+, thus usually sufficient for
a transplant in a 14-year-old child [7].
It is evident that it is necessary to increase the prolifera-
tive ability of stem cells in the UCB so that these cells are
viable and sufficiently mature to engraft after transplant.
In vitro experiments showed that the viability of the
HSCs, deriving from UCB, could be augmented with
favourable effects on the engraftment potential [8,9].
These studies revealed that the beneficial effect of the
in vitro generation of megakaryocytes from UCB, to-
gether with a higher ability to survive the cryopreserva-
tion, were observed when docosahexaenoic acid (DHA)
and arachidonic acid (AA) were supplemented in the
growth medium [8,9], increasing the clinical utility of
the UCB [9]. In particular, DHA, which belongs to the
polyunsaturated fatty acids (PUFAs) family, is a funda-
mental element of cell membranes [10,11], especially
those of the brain and retina [12]. The chemical struc-
ture of DHA is illustrated in Figure 1. DHA accumula-
tion in the brain and retina occurs mainly between the
last intrauterine trimester and the initial months of life.
The metabolic demand of DHA increases progressively
in the course of pregnancy, particularly during the third
trimester. In this phase a sudden acceleration of foetal
growth is observed together with a great deposition of
fatty acids in the central nervous system [13]. Therefore,
the level of DHA during pregnancy can directly influ-
ence the stages of development [14]. Observational stud-
ies have also demonstrated a close association between
the DHA availability during the perinatal period withlong-term cognitive and visual development [15,16]. Be-
sides, the consumption of large quantities of fish, rich in
DHA, has been associated with an increase in gestational
age, a greater foetal weight at birth and less incidence of
pre-eclampsia [17,18].
The effect of DHA on foetal weight and development
is linked to its effect on the endothelium. DHA increases
the flow of blood through vasodilatation in young adults
and improves membrane receptor activity. Therefore, it
is possible that these fatty acids improve foetal growth,
increasing the placental flow by potentiating the activity
of prostacyclin versus thromboxane and reducing blood
viscosity [19].
Furthermore, treatment with DHA in the third trimes-
ter of the pregnancy improves the mother’s DHA status,
as indicated by the composition of fatty acids in the ma-
ternal erythrocyte membrane [20-22].
However, it should be considered that, during the
course of the third trimester, the foetus absorption of
DHA is 70 to 100 mg from the maternal bloodstream
daily; at the same time, during the second half of the
pregnancy, the mother’s needs of DHA supplementation
also grows to support the higher request from the foetus
without any detrimental effect on her own reserves.
Hence, during the third trimester, with an excess or
greater availability of DHA, the foetus will tend to accu-
mulate it preferentially in the brain tissue competing
with the accumulation on the surface of other cells, spe-
cifically, HSCs.
In Denburg et al. [23], the effects of a supplementation
with n-3 PUFA were assessed in a population of neo-
natal CD34+ cells as a method for preventing allergies.
In this study, the pregnant women were treated, from
the 20th week of gestation until delivery, with fish oil
capsules or a placebo of olive oil capsules in a random-
ized control trial (RCT). The results revealed that, in the
group given fish oil, the percentage of CD34+ present in
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trol group (0.879 ± 0.096 versus 0.533 ± 0.041; P <0.002)
[23]. The study confirmed that a maternal dietary sup-
plementation with n-3-PUFA increases the levels of
these fatty acids in the infant’s cell membranes and this
has a significant effect on the CD34+ cell population in
the cord blood.
The aim of this study is to increase the viability of the
stem cells collected at birth from the UCB, in particular
of the haematopoietic lineage, by administrating purified
DHA during the second (20th week of estimated gesta-
tional stage) or third (28th week of estimated gestational
stage) trimester of pregnancy. The purified DHA con-
sists of at least 250 mg/day derived from purified fish oil
or from microalgae extraction administered to pregnant
women orally in the form of capsules in a randomized,
double-blind, monocentric study. The choice to adminis-
ter 250 mg/day is prompted by the European Commu-
nity’s recommended dose for treatment in pregnancy,
based on the outcomes of the Perinatal Lipid Intake
Working Group and the Early Nutrition Programming
Project. This dose is sufficient to maintain maternal-
foetal unity and satisfy the needs of both without incur-
ring the risk of a deficiency in this nutrient.
In this trial, we hypothesize that a DHA supplementa-
tion, during the second or third trimester of pregnancy,
can increase the metabolic activity of the stem cells in
UCB samples overcoming the limit imposed by the ex-
traction of cord blood. Indeed, unlike other sources,
UCB cells have only one possibility of extraction, and it
is thus essential that the cell product obtained is qualita-
tively and quantitatively sufficient for a transplant in
adulthood. This treatment can also foster the engraft-
ment of stem cells of the haematopoietic lineage after
transplant, reducing the window period after transplant-
ation in which haematopoietic stem cells must colonize
the bone marrow, and specialize into cells of the circula-
tory system and of the immune system.Table 1 Eligibility criteria
Inclusion criteria Exclusion c
Caucasian When it is im
emergencies
Non-smokers Women who
Over 18 years of age Mother with
Single pregnancy UCB sample
Absence of diabetes or hypertension, or any other type of
pathology requiring pharmacological therapy
Absence of chromosome abnormalities and/or congenital
malformations in the foetus
HBV, HCV, HIV and CMV negative
CMV, cytomegalovirus; DHA, docosahexaenoic acid; HBV, hepatitis B virus; HCV, hepMethods
Recruitment
The trial is designed to target pregnant women within
the 20th or 28th week of gestation. At the time of re-
cruitment, the participants will sign an informed consent
form, and complete a questionnaire authorizing third par-
ties to obtain demographic, anamnestic and nutritional
data. The information thus obtained will be entered into a
case report form for each pregnant woman.
Detailed information on benefits and risks of DHA will
be provided to study candidates. Participants that meet
pre-specified eligibility criteria (Table 1) and provide writ-
ten informed consent will be enrolled in the study.
The Ethics Committee of the San Giovanni Calibita
Fatebenefratelli Hospital (Rome, Italy), in compliance
with the Helsinki Declaration, approved the study proto-
col (9 July 2009, reference: 35/2009; and 9 December
2010, reference: 67/2010). The trial is registered at the
International Standard Randomised Controlled Trial
Number Register (ISRCTN58396079).
Study design
Participants included in the trial will be divided into two
groups: one group will be given the placebo; and the
other group will be given DHA (Figure 2). The placebo
or DHA will be assigned in a double-blind, randomized
manner, created by a computer program producing a se-
quence of codes attributed to one of the two groups. An
identifying code, assigning the woman to one of the two
study groups, guarantees, from that moment on, ano-
nymity in treating sensitive data.
Each participant will receive a complete set of capsules
of either placebo or DHA, to take one a day from the
20th or 28th week up to the 40th week of estimated ges-
tational age. The placebo pills (placebo batch) will con-
tain 250 mg of olive oil. This choice is conditioned by the
need to use a product of proven safety with a consistency
and flavour as similar as possible to fish oil.riteria
possible to collect cord blood (bureaucratic reasons or because of
regarding the health of the mother or the baby)
have taken other supplements containing DHA or fish oil
a temperature of 39°C during delivery
s with a volume of less than 80 ml and/or less than 70% cell vitality
atitis C virus; UCB, umbilical cord blood.
Figure 2 Work flow for the study. After recruitment the participants will be randomized into one of the two groups. Samples of venous blood
will be taken from all participants before taking placebo or DHA (20th or 28th week) and at the 37th to 38th week of pregnancy to monitor the
level of DHA. After birth, UCB samples will be collected and processed within 48 hours. DHA, docosahexaenoic acid; UCB, umbilical cord blood.
Table 2 Features of the DHA and placebo batch
Feature DHA Placebo
Tablet formulation 250 mg Incromega
DHA + 10 mg natural
vitamin E
250 mg olive oil
Capsule type 10 mm, oval shape 10 mm, oval shape
Capsule colour Dark yellow Dark yellow
Batch production 20,000 tablets 20,000 tablets
Size of the blisters 82 × 132 mm 82 × 132 mm
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of DHA (Incromega™ DHA 250TG SR, Croda, Goole,
UK) + 10 mg natural vitamin E (Avantgarde sigma-tau,
Rome, Italy). The DHA in the capsule is extracted from
fish oil by PureMax™ technology (Croda) that enables
lipids to be purified and concentrated to maximum stan-
dards. This ensures that the DHA used for this study is
free of contaminants, including: heavy metals, such as
mercury, arsenic, cadmium and lead; oxidant impurities;
dioxins and furans; dioxin-type polychlorinated biphe-
nyls; and polycyclic aromatic hydrocarbons.
The packaging of the capsules in the two groups will




Packaging White box White box
DHA, docosahexaenoic acid.Evaluation of erythrocyte membrane DHA levels
To evaluate the effectiveness of the diet supplement, a
venous blood sample will be taken from half of the
study participants with the purpose of finding the DHA
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ples of 2 cc of venous blood will be taken from all partici-
pants before taking placebo or DHA, at the 20th or 28th
week after recruitment, and at the 37th to 38th week of
pregnancy. The blood samples will be taken with a specific
kit provided by Lipinutragen-CNR (Bologna, Italy) and
shipped to the Lipinutragen-CNR laboratory for testing. The
DHA concentration, with respect to the total erythrocyte
membrane phospholipids, will be determined by treating a
0.5 ml portion of the maternal blood sample or cord blood
samples to separate the erythrocytes and isolate the erythro-
cyte membranes [24]. The fraction of total phospholipids
will be treated with 0.5 M KOH/MeOH for 10 minutes at
room temperature in order to obtain the chemical deriv-
ation of the phospholipids and compare them with the cor-
responding chemical fatty acid methyl esters (FAME).
FAMEs will be evaluated by gas chromatography (GC) with
a flame ionization detector (Agilent 6850; Agilent Technolo-
gies, Santa Clara, CA, USA) and a DB-23 column (90% bis-
cyanopropyl/10% phenylcyanopropyl polysiloxane capillary
column; 60 m, 0.25 mm ID, 0.25 μm film thickness) or simi-
lar, with hydrogen as carrier gas at a constant flow of 1 ml/
min; the oven programme will be fixed for the efficient sep-
aration of the FAMEs, including the cis and trans isomers.
FAMEs can be recognized by comparing them with com-
mercially available references. Trans geometric isomers will
be recognized by comparison with a library of trans isomers
obtained by radical isomerization as described in previous
publications [25]. The FAMEs will be identified by a ran-
domized analysis of the samples by GC coupled with mass
spectrometry. The values of the fatty acids will be given as a
percentage of all the most important peaks resulting from
the GC analysis, representing 98 to 99% of the total chroma-
tographic peaks. The analyses will be repeated so that the
value of the DHA can be checked at zero time and com-
pared with the known normal range in healthy subjects.
The statistical assessment of the treatment effective-
ness will be obtained by comparison with the DHA
values obtained after therapy.
Separation of CD34+ protocol
UCB cells will be stained with fluorescein isothiocyanate
(FITC)-conjugated monoclonal antibody against CD45+ and
phycoerythrin (PE)-conjugated monoclonal antibody against
CD34+. These will be used to identify leukocytes and HSCs,
respectively. For analysis of the viability of the cells, they will
also be stained with 7-aminoactinomycin D (7-AAD), which
will bind to the DNA of cells that are undergoing or have
undergone apoptosis (Stem Kit™ Beckman Coulter, Brea,
CA, USA). The stained cells will then be lysed (1:10 dilution
of ammonium chloride 10x concentrated and deionized
water) and analyzed by flow cytometer with a FC 500 cyt-
ometer (Beckman Coulter) using CXP software under a sin-
gle ISHAGE gating strategy.Collection of cord blood
Before extracting the cord blood, the recruited pregnant
women must carry out serological tests to prove the ab-
sence of the following infectious diseases: hepatitis B
virus; hepatitis C virus; HIV; cytomegalovirus; human T-
cell lymphotropic virus; and syphilis. The report will then
be presented to the hospital to obtain the licence.
All the participants will receive a free cord blood col-
lection kit provided by SmartBank (SmartBank, Rome,
Italy). Hospital staff assisting the birth will immediately ex-
tract and collect the cord blood with the kit. Samples will be
shipped to the Biovault technical laboratory (Plymouth, UK)
for specific analysis of: volume (ml); pH; cell viability (%);
number of CD34+ cells; number of leukocytes; and bacterial
and viral tests. In order to determine the DHA percentage
in the cord blood erythrocyte membranes, 2 cc of the ex-
tracted cord blood will be sent to the Lipinutragen-CNR la-
boratory in Bologna.
Processing of cord blood
The cord blood processing procedures will be carried out in
the Biovault laboratory in the UK, possessing medical and
healthcare products, and regulatory agency registration, op-
erating according to the World Health Organization (WHO)
international good manufacturing practices protocol, and the
International Organization for Standardization (ISO) ISO
9001:2008 and ISO 13485:2012 standards, and aseptic treat-
ment, grade A certificate, will be performed in a Biosafety
Level 3 (BSL-3) clean room. Biovault is accredited by the
American National Standards Institute (ANSI) regulatory
accrediting body, Advancing Transfusion and Cellular Ther-
apies Worldwide, and the Joint Accreditation Commit-
tee of the International Society for Cellular Therapy
(ISCT) and the European Group for Blood and Mar-
row Transplantation (EBMT) (JACIE), and has a Hu-
man Tissue Authority licence.
The sample will enter the BSL-3 clean room through a
hermetically sealed window with positive outlet atmos-
pheric pressure. Inside the BSL-3 clean room the sample
will be weighed, centrifuged, measured volumetrically, and
subjected to microbiological tests, flow cytometry analysis
and phase separation with subsequent selection of mono-
nuclear cells. The sample containing the cells will be
inserted into the final Pall container (Pall Corporation, Port
Washington, NY, USA) and mixed at 4°C with 10% di-
methyl sulfoxide (DMSO). The bag or Pall, with a unique,
indelible identification code, will be inserted into a comput-
erized temperature reduction system. After the temperature
is reduced, the Pall will be inserted in a sealed metal con-
tainer and preserved in liquid nitrogen vapour at −196°C.
Flow cytometry
The flow cytometry analysis will be carried out within
48 hours of the UCB sample collection with a FC 500
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platform. The analysis method uses double fluorescence
(FITC-PE) with rat monoclonal antibody. For a simul-
taneous identification and count of the CD45+ and
CD45+ CD34+ cells, a double antibody marking will be
carried out, evaluating the percentage of the positive
population with regards to the absolute count. The
CD34+ receptor will be used as an indicator of the total
number of progenitor stem cells of the haematopoietic
lineage. The cell viability will be evaluated by flow cy-
tometry using 7-AAD (Invitrogen Life Technologies,
Carlsbad, CA, USA). Apoptotic, necrotic and metabol-
ically inactive cells will be stained and thus considered
non-viable while viable cells remain unstained. Total
cells will be counted by flow cytometry discriminating
between non-viable (7-AAD positive cells) and viable
cells (7-AAD negative cells). The flow cytometer will
be calibrated every 24 hours and quality controls per-
formed according to the UK National External Quality
Assessment Service (NEQAS) protocol.
Statistical analysis
The statistical analysis of the data obtained will be car-
ried out with the aid of the Statistical Package for the So-
cial Sciences (SPSS) program (IBM Corporation, Armonk,
NY, USA) in cooperation with the Fatebenefratelli Associ-
ation for Research (AFaR) of the San Giovanni Calibita
Fatebenefratelli Hospital (Rome, Italy). Each experimental
group will be compared versus the respective placebo
group. The effectiveness of the DHA supplementation at
different stages of gestation will also be evaluated by com-
paring the two experimental groups. The differences be-
tween the quantitative variables of the two groups will be
analyzed with the Student’s t-test and analysis of variance
(ANOVA); results of P <0.05 will be considered statisti-
cally significant. The Spearman test will also be used to
compare the parameters of interest, and other quantitative
and non-quantitative variables presented by the groups
studied.
Discussion
The proposed study is a randomized, double-blind, placebo-
controlled, clinical trial designed to investigate the possible
positive effects on the quantity and viability of stem cells in
UCB samples, in pregnant women supplemented with a
dose of 250 mg/day of DHA, from the 20th or from the
28th week of pregnancy. No prospective data is presently
available; however, if the study shows benefits, in terms of
the quality and quantity of the stem cells, DHA could be
regularly administered to pregnant women to potentiate the
chances of success of transplants from UCB.
Trial status
Patient recruitment is currently being undertaken.Abbreviations
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